GlassScriptPhysician profile
Danielle Mankin
NPI 1770831588
$4,958.96
in general payments reported to CMS, 2019-2025
39 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $160 · 2021: $1,348 · 2022: $1,686 · 2023: $1,282 · 2024: $292 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,765.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $721.99 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $504.36 | 2020-2025 | |
| Lilly USA, LLC | $381.66 | 2021-2023 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $368.72 | 2020-2025 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $272.55 | 2021-2023 | |
| Glaxosmithkline, LLC. | $262.38 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $260.40 | 2020-2025 | Otezla, Repatha, Krystexxa |
| Pfizer INC. | $204.19 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $191.97 | 2021-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $177.84 | 2022 | |
| Ferring Pharmaceuticals INC. | $164.70 | 2021-2023 | Euflexxa |
| Otsuka America Pharmaceutical, INC. | $147.84 | 2021-2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.04 | 2021-2023 | Xifaxan, Trulance |
| Insulet Corporation | $104.49 | 2022-2023 | Omnipod |
| Abbott Laboratories | $97.01 | 2022-2023 | Freestyle Libre 3 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Mankin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.